Plant production of high affinity nanobodies that block SARS-CoV-2 spike protein binding with its receptor, human angiotensin converting enzyme

- 1 Marco Pitino¹, Laura A. Fleites¹, Lauren Shrum¹, Michelle Heck², Robert G. Shatters, Jr.^{3,*}
- ¹AgroSource, Inc., Jupiter, FL, USA
- ² Emerging Pests and Pathogens Research Unit, USDA Agricultural Research Service, Ithaca, NY,
- 4 USA
- ⁵ ³ U.S. Horticultural Research Laboratory, Unit of Subtropical Insects and Horticulture, USDA
- 6 Agricultural Research Service, Fort Pierce, FL, USA
- 7 *** Correspondence:**
- 8 Robert G. Shatters, Jr.
- 9 Robert.Shatters@USDA.gov

10 Keywords: SARS-CoV-2, nanobody, plant, V_{HH}, competitive ELISA, ACE2 (Min.5-Max. 8)

11 Abstract

Nanobodies® (V_{HH} antibodies), are small peptides that represent the antigen binding domain, V_{HH} of 12 13 unique single domain antibodies (heavy chain only antibodies, HcAb) derived from camelids. Here, we demonstrate production of V_{HH} nanobodies against the SARS-CoV-2 spike proteins in the 14 solanaceous plant Nicotiana benthamiana through transient expression and their subsequent detection 15 16 verified through western blot. We demonstrate that these nanobodies competitively inhibit binding 17 between the SARS-CoV-2 spike protein receptor binding domain and its human receptor protein, angiotensin converting enzyme 2 (ACE2). We present plant production of nanobodies as an 18 19 economical and scalable alternative to rapidly respond to therapeutic needs for emerging pathogens 20 in human medicine and agriculture.

21 **0** Introduction

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a member of the subfamily 22 23 Coronaviridae in the family Coronaviridae and the order Nidovirales. Pathogenic viruses in this 24 subfamily cause severe respiratory syndrome in humans. SARS-CoV-2 is related to SARS-CoV-1 and Middle Eastern Respiratory Syndrome (MERS-CoV), which emerged in humans in 2003 and 25 2012, respectively. SARS-CoV-2 is responsible for the 2019 pandemic and COVID-19 disease 26 27 (Huang, Wang et al. 2020). COVID-19 disease results in a range of outcomes, ranging from asymptomatic infection to patient death. To date, global vaccinations for SARS-CoV-2 protections 28 29 are underway, but additional treatments are needed to prevent infection among naïve and even 30 vaccinated individuals. Tiered prevention efforts have been shown to reduce transmission and 31 severity of disease outcome.

32

33 Coronaviruses are positive-sense, single-stranded RNA viruses with spherical virions bound by a 34 membrane envelope that are 100-160nm in diameter. The 3' end of the viral genome encodes the

35 structural proteins, including the envelop glycoprotein spike (S), envelop (E), membrane (M) and 36 nucleocapsid (N). Inserted into the membrane envelop are ~25 copies of the homotrimeric 37 transmembrane spike glycoprotein (spike protein) as a clover-shaped trimer, with three S1 heads and 38 a trimeric S2 stalk (Benton, Wrobel et al. 2020). The receptor binding domain (RBD) is situated atop 39 each S1 head (Nishima and Kulik 2021). The RBD is responsible for entry into host cells (Wang, 40 Zhang et al. 2020, Jackson, Farzan et al. 2022) via interaction with the protein angiotensin converting 41 enzyme 2 (ACE2), the interaction which also determines the viral host range (Yan, Zhang et al. 42 2020). Studies have shown a higher affinity for SARS-CoV-2 to ACE2 as compared to ACE1, 43 further supporting its role in transmission and virulence (Samavati and Uhal 2020). Highly 44 transmissible viral variants, such as Delta and Omicron variant, have been selected for during the 45 pandemic and exhibit mutations in the RBD (Li, Lai et al. 2021) (Saxena, Kumar et al. 2022). Thus, 46 interactions between ACE2 and the RBD are attractive targets for the development of novel anti-viral 47 therapies.

48

49 Nanobodies represent a promising new therapy for the treatment of viral diseases, including COVID-50 19. A pubmed search for SARS-CoV-2 and nanobody brings up a total of 21 peer-reviewed 51 publications (Esparza, Martin et al. 2020). Nanobodies, also referred to as V_{HH}, are produced by 52 animals in the camelid family, which include llamas and alpacas. Coined by the popular press as 53 mini-antibodies (Deyev and Lebedenko 2009), these IgGs are less than 15 kDa and are comprised of 54 an unpaired heavy-chain variable domain. Nanobodies have been reported to bind antigens with 55 affinities equivalent to a conventional IgG (Gonzalez-Sapienza, Rossotti et al. 2017, Asaadi, 56 Jouneghani et al. 2021). Nanobodies are also under development for the control of at least two crop 57 diseases: grapevine fanleaf virus in cultivated wine grapes (Yan, Zhang et al. 2020), botrytis, and 58 detection against a range of other plant pathogens (Njeru and Kusolwa 2021). 59

These antigen-binding proteins, derived from single-chain camelid antibodies, are significantly smaller in size compared to conventional antibodies with a molecular mass of 12-15 KDa (conventional antibodies are ~150 kDa). Key features of nanobodies that make them attractive alternatives to conventional antibodies include their high affinity, specificity, solubility, thermostability and mobility. Production of nanobodies is typically done by expression of the gene in *E.coli*; however, a potentially more effective method is currently being studied based on plant expression.

67

We represent a team of agricultural scientists developing sustainable and biologically-based solutions to pathogens of economic importance in crop production. As part of this research, we developed a low-cost, plant-based method of producing proteins that could be used to solve agricultural pathogen problems in agricultural production settings. As a proof-of-concept, we describe the production of a RBD nanobody in a plant expression system. The benefits of producing therapeutics in plants justify

73 considering plants to mass produce COVID-19 protein-based therapies.

74 1 Materials and Methods

75 **1.1 Construct Design**

A total of four constructs were designed for experimentation with plant expression of COVID-19 nanobodies. The methionine start codon of the SARS-CoV2 nanobody protein sequence (NIH-CoVnb-112; Esparza et al. 2020) was removed and replaced with an N-terminal signal peptide sequence for protein secretion into the apoplast and a 6x histidine tag at the C-terminus (SP-CoV19_his). An analogous negative mutated control construct was also designed, such that the

81 amino acids spanning the three complementarity determining regions (CDR1, CDR2, CDR3) of the

82 native SARS-CoV2 nanobody sequence were scrambled using a random number generator SP-

83 *mCov19_*his; (Fig. S1). Disruption of the CDR regions was expected to abolish the interaction with

84 the receptor binding domain of the viral spike protein.

85 Two more variants of the SARS-CoV2 nanobody construct were made as fusions to monomeric 86 enhanced green fluorescent protein coding sequence (EGFP): one with an N-terminal 6x histidine tag (SP-his_CoV19-GFP), and a second with a C-terminal 6x histidine tag (SP-CoV19_his-GFP; (Fig. 87 88 S1). This module was followed in both constructs by EGFP, with a P2A site (ribosome skipping 89 sequence allowing both CoV19-variants and EGFP to be produced as separate proteins) inserted 90 between the nanobody module and EGFP sequence. All constructs were codon-optimized for 91 expression in the Solanaceae using an online tool provided by Integrated DNA Technologies (IDT, 92 Illinois, USA; https://www.idtdna.com/CodonOpt) prior to uploading to the online ordering portal for 93 Codex DNA (La Jolla, CA). A 40bp span of nucleotide sequence homologous to the recipient vector 94 pNANO was added to the 5' and 3' ends of the constructs to enable cloning with the BioXP 3250 95 system (Codex DNA, La Jolla, CA).

96

97 **1.2 Construct Generation and Bacterial Transformation**

The plasmid backbone was linearized by sequential digestion with *Sma*I and *Spe*I (New England Biolabs, Ipswich, MA, USA), and gel purified from 0.8% SeaPlaque GTG Agarose (Lonza, Rockland, ME) using a phenol:chloroform:isoamyl alcohol extraction method followed by overnight precipitation at -20°C in 100% ethanol, 0.3M NaOAc, pH 5.0. The purified, precipitated DNA was washed with 70% ethanol, dried briefly, and resuspended in sterile nuclease free water. The final constructs were generated in an overnight run on the BioXP 3250 system (Fig. 1A) (Codex DNA, La Jolla, CA), an automated synthetic biology platform for DNA fragment assembly and cloning.

105 *Agrobacterium tumefaciens* EHA105 was electroporated with the BioXP products and grown on LB 106 supplemented with kanamycin ($100\mu g/ml$) for three days (Fig. 1B). Colonies were screened using 107 colony PCR and sequence verified prior to transient expression and purification in *N. benthamiana*.

108

109 **1.3 Plant Growth and Agroinfiltration**

110 *N. benthamiana* plants were grown under the greenhouse conditions and used at 4-5 weeks old for 111 transient expression using plant infiltration with Agrobacterium EHA105, which mechanically 112 delivers the bacteria to the plant's extracellular matrix (apoplast) (Kapila, De Rycke et al. 1997) 113 (Fig.1C). Agrobacterium EHA105 harboring pNANO plasmid was cultured overnight in 5 mL of LB 114 media with 100µg ml⁻¹ of kanamycin. Overnight culture was pelleted and resuspended in infiltration 115 buffer (10mM MgCl2, 10mM MES, 400 µM acetosyringone) at optical density at 600 nm (OD₆₀₀) 116 0.3. For each construct, leaves were infiltrated with the bacterial suspension and set in greenhouse 117 for duration of experiment (Fig. 1C). Two days post infiltration (2 dpi), leaves were manually excised 118 from the plants using a sterile blade and processed for total protein extraction and purification.

119 **1.4 Protein Extraction and Purification**

120 N. benthamiana leaves were observed under UV light for GFP expression and harvested at 2 dpi (days post infiltration) (Fig. 1D) followed by homogenization in liquid nitrogen. Total plant proteins 121 were extracted using native buffer (10mM Tris/HCl pH 7.5, 150mM NaCl, 0.5mM EDTA, 1% [v/v] 122 123 P9599 Protease Inhibitor Cocktail [Sigma-Aldrich], 1% [v/v] IGEPAL CA-630 [Sigma-Aldrich]). A 124 total of 5mL of extraction buffer per gram of leaf tissue was used. Samples were clarified by 125 centrifugation at 4°C at 3000 rcf. The supernatant was filtered through a 40 µm nylon cell strainer 126 (Becton Dickinson Labware, Franklin Lakes, NJ, US) and then used for purification process utilizing 127 Ni-NTA agarose columns (Thermo Scientific, Rockford, US), following manufacturers guidelines. Briefly, imidazole binding buffer (20mM sodium phosphate, 10mM imidazole, 0.5mM NaCl, pH 7.4) 128 129 was used to equilibrate, bind, and wash the columns. To elute product of interest, (20mM sodium

130 phosphate, 500mM imidazole, 0.5mM NaCl, pH 7.4) was used.

131 **1.5 SDS-PAGE and Western Blotting**

132 Samples were denatured and reduced using 5x Lane Marker Reducing Sample Buffer (Thermo 133 Scientific, Rockford, IL, US), boiled at 95°C for 10 minutes, then stored on ice. Gradient 4-20% 134 precast polyacrylamide gels (Bio-Rad Laboratories, Hercules, CA) were loaded into electrophoresis 135 tank (Bio-Rad Laboratories) and filled with 1x Tris/Glycine/SDS buffer. Kaleidoscope ladder (Bio-136 Rad Laboratories) was loaded into the first well (5uL), and each sample was loaded into every other 137 well. 25µL per sample were used for Coomassie staining, and 10µL per sample were used for 138 immunoblotting. Electrophoresis was run following manufacturing guidelines with a powerpack 139 (Bio-Rad Laboratories). One gel was stained with Coomassie blue, while the other gel was 140 transferred to a nitrocellulose membrane using the Trans-Blot Turbo Transfer system following 141 manufacturer guidelines (Bio-Rad Laboratories). The nitrocellulose membrane was removed and 142 placed in 1X Casein blocker for one hour on rotator followed by incubation with a 1:1000 dilution of 143 his HRP-conjugated antibodies (Proteintech, Rosemount, IL, US) for 1 hour room temperature. The 144 membrane was washed in 1X TBS three times in 10-minute intervals. ECL substrate (Bio-rad 145 Laboratories) that consists of 1 mL peroxide and 1mL luminol enhancer were spread onto membrane 146 and left for 5 minutes before observation using ChemiDoc imager (Bio-rad Laboratories).

147 **1.6** Competitive ELISA binding screen for ACE2 and RBD

To verify the activity of recombinant nanobodies generated in plants, we conducted a competitive 148 149 binding assay that measures inhibition of the interaction between the receptor binding domain (RBD) 150 of the SARS-CoV-2 spike protein with the ACE2 receptor in the presence of the purified nanobodies. 151 Purified nanobodies were diluted at 1µg/mL and 0.1 µg/mL concentrations in association with RBD 152 proteins then added to the ACE2 coated plate (RayBiotech, Peachtree Corners, GA, US). Nanobodies 153 and RBD proteins were incubated at room temperature for one hour to allow interaction. The assay 154 plate was washed four times with a wash solution provided by ELISA kit (RayBiotech). HRP-155 conjugated Anti-IgG was added to plate post wash and incubated at room temperature for one hour 156 with gentle shaking. After four additional washes, the plate was developed by addition of 157 tetramethylbenzidine and stopped after 30 minutes of gentle shaking in the dark with stop solution 158 (RayBiotech). Absorbency was measured immediately after adding stop solution at 450 nm on a plate 159 reader (Citation 1 imaging reader, BioTek, Winooski, VT, US).

160

161 **2 Results**

162 2.1 Expression and purification of nanobodies for SARS-Cov-2 RBD in N. benthamiana

163 An initial test performed using SP-CoV19_his purified from transient expressing leaves showed an 164 expected ~15KDa band confirming expression and purification. This band was visualized by Coomassie blue staining of an SDS-Page gel and western blot/immunodetection specific for the his-165 tag on the SP-CoV19 protein (Fig. S2). Next, we tested SP-his CoV19-GFP, SP-CoV19 his-GFP, 166 SP-mCov19 his sequences. GFP visualization of infiltrated leaves showed high levels of expression 167 168 two days post infiltration and leaves were harvested at this time and used for purification. Bands on 169 the Coomassie gel and western blot were visualized migrating between the 15 and 20 kDa marker 170 bands corresponding to the size of the SP-his CoV19-GFP, SP-CoV19 his-GFP and SP-mCov19 his 171 sequences (Fig 2A,B).

172 2.2 Biological activity of SARS-Cov-2 nanobody with ACE2 competition assay

173 Next, we assessed the ability for plant produced nanobody to block ACE2 binding cells RBD 174 interaction. To evaluate relative inhibition of RBD protein from binding to ACE2 a competitive 175 ELISA inhibition assay was performed. RBD protein binding ACE2 was indicated by high colorimetric absorbance. Initial screening was performed using SP-CoV19_his at 100,10,1 and 0.1 176 177 µg/mL concentrations (Fig. S2C). Competitive ELISA assay indicated that 1µg/mL SP-CoV19_his 178 inhibited interaction between ACE2 and RBD and was used for subsequent experiments. The same 179 results were obtained using both SP-his_CoV19-GFP and SP-CoV19_his-GFP, showing 100% 180 inhibition between ACE2 and RBD at 1µg/ml. Inhibition was also observed at 0.1µg/ml with 60-70% 181 inhibition (Fig. 3). In contrast, the mutated sequence SP-mCov19_his inhibited less than <20% at 1.0 182 µg/ml and 0% at 0.1 µg/ml (Fig. 3). These results showed that plant-produced SP-CoV19 his, SP-183 his CoV19-GFP and SP-CoV19 his-GFP, but not SP-mCov19 his, inhibit 100% ACE2 and RBD 184 interactions at 1µg/mL similarly to previous published data with NIH-CoVnb-112 production in yeast 185 system (Esparza et al. 2020).

186 **3 Discussion**

187 In this study, we provide proof of concept for in plant production of nanobodies that neutralize the 188 interaction between the human ACE2 receptor and the SARS-CoV-2 spike protein RBD, a key step 189 of the infection initiation process (Esparza, Martin et al. 2020). Binding inhibition was slightly 190 reduced with a 10-fold dilution of the nanobody, consistent with previous reports for the same 191 nanobody expressed in yeast (Esparza, Martin et al. 2020). Moreover, a modified nanobody with a 192 scrambled RBD binding domain failed to inhibit binding at the lower concentrations used, 193 demonstrating the binding specificity of the interaction between the plant-produced RBD-binding 194 nanobodies and the RBD. The plant expression constructs used two features to aid in nanobody 195 production: the use of a signal peptide targeting the nanobody to the plant apoplastic space and a self-196 cleaving P2A peptide. A signal peptide was added for future nanobody production in plant cell tissue 197 culture systems, to support secretion of the nanobody through the cellular secretory pathway. The 198 self-cleaving P2A peptide enabled production of functional nanobodies with concurrent fluorescent 199 protein signal to monitor transformation events in N. benthamiana and to easily localize 200 regions of nanobody production in planta. Plant tissue was harvested at 2 days post-infiltration, and 201 thus not optimized for nanobody yield in this study. The His tag facilitated enrichment from the plant 202 proteome but would need to be removed prior to the development of plant-based nanobody therapies 203 for the treatment of human or other animal diseases. A recent example of production of RBD in 204 planta exhibits suitable biochemical and antigenic features for use in a subunit vaccine platform 205 (Demone, Nourimand et al. 2021). We posit that molecular farming of nanobodies, and other 206 biologicals is an under-developed area for cost savings and increased global access for the production 207 of protein and small molecule therapies.

208 Research using nanobodies in plants has been increasing rapidly in recent years (Dhama, Natesan et 209 al. 2020, Wang, Yuan et al. 2021), including in the development of therapies and diagnostic tools for 210 plant diseases. Plants offer several advantages for nanobodies expression over conventional 211 expression platforms including their easy transformation, low risk of pathogen contamination and 212 low cost for upscaling. In addition to injectable vaccines, new strategies are emerging and being 213 developed to increase protection against COVID-19, for example a nasal spray-delivered nanobody 214 offers a complementary barrier method to prevent virus acquisition into human epithelial cells in the 215 airway. Nanobodies are 12-15 kDa single-domain antibody fragments that can be delivered by 216 nebulizers and relatively easy and inexpensive to produce compared to other systems (Esparza et al. 217 2020). Previous cryo-electron microscopy studies showed SARS-CoV-2 spike protein and its 218 interaction with the cell receptor ACE2, such binding triggers a cascade of events that leads to the 219 fusion between cell and viral membranes for cell entry (Kirchdoerfer et al. 2018; Yuan et al. 2017; 220 Gui et al. 2017). Because SARS-CoV-2 binding spike protein RBD and the host ACE2 receptor 221 determines host susceptibility to the virus, interfering with that interaction might constitute a 222 treatment option (Walls et al. 2020). Esparza and colleagues (2020) showed that NIH-CoVnb-112 223 candidate nanobodies blocked interaction between ACE2 and RBD "wild type" and 3 variant forms, 224 also they showed that it retained structural integrity and potency after nebulization. A subset of these 225 nanobodies fold in planta and retain the structural features necessary to interfere with protein 226 interaction between ACE2 and the SARS-CoV-2 spike protein RBD. We demonstrate that 227 nanobodies produced in plants retain proper folding and functionality comparably to a yeast 228 production system supporting the use of plants as cost-effective production platforms for therapeutic 229 needs with emerging pathogens, such as the SARS-CoV-2 virus.

230 4 Conflict of Interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

233 **5** Author Contributions

MH, MP and RS conceived of the idea and provided grant funding. LF developed and constructed the
 nanobody constructs. MP, LF and LS conducted the experiments. All authors contributed to data
 analysis and writing and editing the paper.

237 **6 Funding**

Funding was provided by the U. S. Department of Agriculture CRIS project 8062-22410-007-000-D
and USDA, NIFA grant 2020-70029-33176.

240 **7** Acknowledgements

We would like to thank Carrie Vanderspool and Mant Acon for the plants used in this study. Mention of trade names or commercial products in this article is solely for the purpose of providing specific information and does not imply recommendation or endorsement by the U.S. Department of Agriculture.

245 8 Supplementary Material

246 Supplementary Material should be uploaded separately on submission, if there are Supplementary

247 Figures, please include the caption in the same file as the figure. Supplementary Material templates

248

249 Figure 1. Schematic representation of workflow of production of nanobodies in plant system.

A) Cloning with the BioXP 3250 Gibson Assembly[®]. B) Agrobacterium transformation. C) Agrobacterium infiltration was performed by using 1 mL needleless syringes to inject bacteria into the abaxial side of the leaves at OD_{600} 0.3. D) P2A sequence was used for generating multiple separate proteins from a single mRNA, GFP included in the sequence allowed prescreening of high expression protein in leaves using UV light.

- 255
- **Figure 2 SDS PAGE and Western blot. A)** Coomassie blue stain was used to verify purity of
- concentrated proteins and band size. B) Western blotting was carried out to detect the target purified
 SP-CoV19_his-GFP, SP-his_CoV19-GFP and negative control SP-mCov19_his using his antibodies.
- 259

Figure 3 Competitive ELISA inhibition of ACE2 and RBD binding using anti RBD nanobodies. Competition binding assays were used to investigate whether the SP-Cov19_his-GFP and SPhis_CoV19-GFP blocked the binding of RBD to ACE2 compared to the mutant version SP $mCov19_his$. SP-CoV19_his-GFP, SP-his_CoV19-GFP and SP- $mCov19_his$ at 1µg/mL and 0.1µg/mL were incubated with RBD proteins, both SP-CoV19_his-GFP, SP-his_CoV19-GFP inhibited RBD bound to ACE-2 but SP- $mCoV19_his$ at 1µg/mL.


- 266267 Supplementary data
- 268
- Figure S1. Multiple sequence alignment of protein coding sequences showing the overall structure of the various nanobody constructs. The complementarity determining regions (CDR) 1, 2, and 3, which were mutated in the negative control construct SP-*mCov19*_his, are annotated along with other major features.
- Figure S2. A) Western blot serial elution: total of 5ml elution buffer with 500mM imidazole was used to recover of 1mL each sample B) Coomassie blue staining was used to validate purification
- after Ni-NTA using total protein and purified protein. **C**) Purified SP-CoV19 his samples were
- 275 after NFA using total protein and purfied protein. C) Furfied SF-COV F9_Ins samples V 276 pulled together and concentrated using 10Kda size exclusion column to 500µl and tested
- with competitive ELISA at $100, 10, 1, 0.1 \mu g/mL$.
- 278


9 References

- Asaadi, Y., F. F. Jouneghani, S. Janani and F. Rahbarizadeh (2021). "A comprehensive comparison
 between camelid nanobodies and single chain variable fragments." <u>Biomarker Research</u> 9(1): 87.
- 282 Benton, D. J., A. G. Wrobel, P. Xu, C. Roustan, S. R. Martin, P. B. Rosenthal, J. J. Skehel and S. J.
- Gamblin (2020). "Receptor binding and priming of the spike protein of SARS-CoV-2 for membrane
 fusion." Nature 588(7837): 327-330.
- 285 Demone, J., M. Nourimand, M. Maltseva, M. Nasr-Sharif, Y. Galipeau, M.-A. Langlois and A. M.
- 286 MacLean (2021). "Plant-based production of SARS-CoV-2 antigens for use in a subunit vaccine."
- 287 <u>bioRxiv</u>: 2021.2010.2017.464700.
- Deyev, S. M. and E. N. Lebedenko (2009). "Modern Technologies for Creating Synthetic Antibodies
 for Clinical application." <u>Acta Naturae</u> 1(1): 32-50.

- 290 Dhama, K., S. Natesan, M. Iqbal Yatoo, S. K. Patel, R. Tiwari, S. K. Saxena and H. Harapan (2020).
- ²⁹¹ "Plant-based vaccines and antibodies to combat COVID-19: current status and prospects." <u>Hum</u>
- 292 <u>Vaccin Immunother</u> **16**(12): 2913-2920.
- 293 Esparza, T. J., N. P. Martin, G. P. Anderson, E. R. Goldman and D. L. Brody (2020). "High affinity
- nanobodies block SARS-CoV-2 spike receptor binding domain interaction with human angiotensin
 converting enzyme." Sci Rep 10(1): 22370.
- Gonzalez-Sapienza, G., M. A. Rossotti and S. Tabares-da Rosa (2017). "Single-Domain Antibodies
 As Versatile Affinity Reagents for Analytical and Diagnostic Applications." Front Immunol 8: 977.
- Huang, C., Y. Wang, X. Li, L. Ren, J. Zhao, Y. Hu, L. Zhang, G. Fan, J. Xu, X. Gu, Z. Cheng, T. Yu,
- J. Xia, Y. Wei, W. Wu, X. Xie, W. Yin, H. Li, M. Liu, Y. Xiao, H. Gao, L. Guo, J. Xie, G. Wang, R.
- Jiang, Z. Gao, Q. Jin, J. Wang and B. Cao (2020). "Clinical features of patients infected with 2019
- 301 novel coronavirus in Wuhan, China." <u>Lancet</u> **395**(10223): 497-506.
- Jackson, C. B., M. Farzan, B. Chen and H. Choe (2022). "Mechanisms of SARS-CoV-2 entry into
 cells." <u>Nature Reviews Molecular Cell Biology</u> 23(1): 3-20.
- Li, J., S. Lai, G. F. Gao and W. Shi (2021). "The emergence, genomic diversity and global spread of
 SARS-CoV-2." <u>Nature</u> 600(7889): 408-418.
- Nishima, W. and M. Kulik (2021). "Full-Length Computational Model of the SARS-CoV-2 Spike
 Protein and Its Implications for a Viral Membrane Fusion Mechanism." <u>Viruses</u> 13(6).
- 308 Njeru, F. N. and P. M. Kusolwa (2021). "Nanobodies: their potential for applications in
- 309 biotechnology, diagnosis and antiviral properties in Africa; focus on application in agriculture."
- 310 <u>Biotechnology & Biotechnological Equipment</u> **35**(1): 1331-1342.
- Samavati, L. and B. D. Uhal (2020). "ACE2, Much More Than Just a Receptor for SARS-COV-2."
 <u>Frontiers in Cellular and Infection Microbiology</u> 10.
- 313 Saxena, S. K., S. Kumar, S. Ansari, J. T. Paweska, V. K. Maurya, A. K. Tripathi and A. S. Abdel-
- 314 Moneim (2022). "Characterization of the novel SARS-CoV-2 Omicron (B.1.1.529) variant of
- 315 concern and its global perspective." <u>J Med Virol</u> **94**(4): 1738-1744.
- 316 Wang, Q., Y. Zhang, L. Wu, S. Niu, C. Song, Z. Zhang, G. Lu, C. Qiao, Y. Hu and K.-Y. Yuen
- 317 (2020). "Structural and functional basis of SARS-CoV-2 entry by using human ACE2." <u>Cell</u> 181(4):
 318 894-904. e899.
- Wang, W., J. Yuan and C. Jiang (2021). "Applications of nanobodies in plant science and
 biotechnology." <u>Plant Mol Biol</u> 105(1-2): 43-53.
- 321 Yan, R., Y. Zhang, Y. Li, L. Xia, Y. Guo and Q. Zhou (2020). "Structural basis for the recognition of 322 SAPS CoV 2 by full length human ACE2." Science **367**(6485): 1444-1448
- 322 SARS-CoV-2 by full-length human ACE2." <u>Science</u> **367**(6485): 1444-1448.

323





BioXp Gibson Assembly[®]


Agrobacterium transformation

Agrobacterium transient expression

UV detection of green fluorescent protein (GFP) Sp-Cov19_his_G Sp-his_Cov19-G Sp-*mCov19_*his

Sp-Cov19_his-G Sp-his_Cov19-G Sp-*mCov19_*his

250 KD			250 KD		
150			150		_
100			100		
75			75		
50 KD			50 KD		
37 KD	Hi bing		37 KD		
25 KD			25 KD		
20 KD			20 KD		-
15 KD			15 KD	_	-
10 KD			10 KD		
10 KD			10 KD		



Sp-Cov19_his-G Sp-his19_Cov-G Sp-*mCov19_*his